Cytokinetics (CYTK) 10.09 $CYTK
Cytokinetics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Tue Jul 05, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at Cantor Fitzgerald's 2 Annual Healthcare Conference on Tuesday, July 12, 2016 at 1:00 PM ET at Le Parker Meridien in New York, NY.
CYTK: 10.09 (-0.24)
Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease
GlobeNewswire - Thu Jun 30, 6:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a randomized, double-blind, placebo-controlled, two period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107) on physical function in patients with chronic obstructive pulmonary disease (COPD). CK-107 is a novel fast skeletal muscle troponin activator which is being developed as a potential treatment for people living with SMA, COPD and certain other debilitating diseases and conditions associated with muscular weakness and/or fatigue. Astellas is conducting this Phase 2 clinical trial in collaboration with Cytokinetics.
CYTK: 10.09 (-0.24)
Cytokinetics Has Returned 19.1% Since SmarTrend Recommendation (CYTK)
Comtex SmarTrend(R) - Mon Jun 27, 1:48PM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 3 months, Cytokinetics has returned 19.14% as of today's recent price of $8.97.
CYTK: 10.09 (-0.24)
Cytokinetics Shares Up 19.9% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Fri Jun 17, 1:24AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 2 months, Cytokinetics has returned 19.87% as of today's recent price of $9.02.
CYTK: 10.09 (-0.24)
Cytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 3:05AM CDT
Cytokinetics, Incorporated (CYTK) saw its shares rise almost 7% in the last trading session.
CYTK: 10.09 (-0.24), ANIP: 55.38 (-1.13)
Cytokinetics to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue Jun 14, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the JMP Securities 2016 Life Sciences Conference on June 21, 2016 at 1:00 PM EDT at the St. Regis Hotel, New York, NY. Members of Cytokinetics' senior management team will also participate in the 3 Annual ROTH Healthcare Day on June 22, 2016 at The Dorchester Hotel in London, UK.
CYTK: 10.09 (-0.24)
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress
GlobeNewswire - Mon May 23, 6:30AM CDT
Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP
CYTK: 10.09 (-0.24), AMGN: 160.18 (-0.92)
Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
GlobeNewswire - Fri May 20, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.
CYTK: 10.09 (-0.24), SRPT: 21.37 (-1.25)
Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016
GlobeNewswire - Fri May 13, 3:00PM CDT
Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology, to be held May 21 - May 24, 2016 at the Fortezza da Basso in Florence, Italy.
CYTK: 10.09 (-0.24)
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire - Wed May 11, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2016 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.
CYTK: 10.09 (-0.24)
Cytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month
GlobeNewswire - Mon May 02, 6:34AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it will ring the Closing Bell at Nasdaq this afternoon in recognition of ALS Awareness Month and the company's commitment to education, awareness, research and development activities focused to amyotrophic lateral sclerosis (ALS). Cytokinetics' senior leadership team will be joined in this symbolic act by the leadership of the National, Golden West and New York Chapters of The ALS Association as well as people living with ALS and their loved ones.
CYTK: 10.09 (-0.24)
The ALS Association and Cytokinetics Ring in May as ALS Awareness Month at NASDAQ
PR Newswire - Sun May 01, 4:03PM CDT
May is ALS Awareness Month, an annual grassroots effort led by the ALS community and The ALS Association to raise awareness about amyotrophic lateral sclerosis (ALS) and move people to action in advancing the search for effective treatments and a cure. On Monday, May 2, The ALS Association is pleased to join Cytokinetics, Inc. (Nasdaq: CYTK), along with people living with ALS and their families, for the ringing of the closing bell at NASDAQ in New York City to kick off this year's campaign.
CYTK: 10.09 (-0.24)
Cytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Apr 29, 9:00AM CDT
What:
CYTK: 10.09 (-0.24), NDAQ: 66.43 (+0.55)
Cytokinetics, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the first quarter of 2016 were $8.4 million, compared to $4.4 million, during the same period in 2015. The net loss for the first quarter was $12.5 million, or $0.31 per basic and diluted share. This is compared to the net loss for the same period in 2015 of $8.9 million, or $0.23 per basic and diluted share. As of March 31, 2016, cash, cash equivalents and investments totaled $108.6 million.
CYTK: 10.09 (-0.24)
Cytokinetics to Announce First Quarter Results on April 28, 2016
GlobeNewswire - Thu Apr 14, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 28, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
CYTK: 10.09 (-0.24)
Cytokinetics to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:20 AM ET at the Westin Grand Central Hotel in New York, NY.
CYTK: 10.09 (-0.24)
Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical trial to evaluate the safety, pharmacokinetics and efficacy of omecamtiv mecarbil in Japanese subjects with heart failure and reduced ejection fraction. Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.
CYTK: 10.09 (-0.24), AMGN: 160.18 (-0.92)
Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALS
GlobeNewswire - Thu Mar 31, 6:30AM CDT
Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced a research collaboration to refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from Cytokinetics' clinical trials of tirasemtiv. Funded by Origent's receipt of a grant from The ALS Association, this joint research program will enable the first prospective validation of the predictive model in a clinical trial setting. Previously, the Origent models predicting both function and survival of ALS patients have been validated using internal and retrospective external datasets.
CYTK: 10.09 (-0.24)
Cytokinetics Has Returned 36.7% Since SmarTrend Recommendation (CYTK)
Comtex SmarTrend(R) - Tue Mar 29, 1:09PM CDT
SmarTrend identified a Downtrend for Cytokinetics (NASDAQ:CYTK) on December 29th, 2015 at $10.44. In approximately 3 months, Cytokinetics has returned 36.66% as of today's recent price of $6.61.
CYTK: 10.09 (-0.24)
37.3% Return Seen to Date on SmarTrend Cytokinetics Call (CYTK)
Comtex SmarTrend(R) - Tue Mar 22, 12:58AM CDT
SmarTrend identified a Downtrend for Cytokinetics (NASDAQ:CYTK) on December 29th, 2015 at $10.44. In approximately 3 months, Cytokinetics has returned 37.33% as of today's recent price of $6.54.
CYTK: 10.09 (-0.24)
Cytokinetics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Tue Jul 05, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at Cantor Fitzgerald's 2 Annual Healthcare Conference on Tuesday, July 12, 2016 at 1:00 PM ET at Le Parker Meridien in New York, NY.
CYTK: 10.09 (-0.24)
Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease
GlobeNewswire - Thu Jun 30, 6:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a randomized, double-blind, placebo-controlled, two period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107) on physical function in patients with chronic obstructive pulmonary disease (COPD). CK-107 is a novel fast skeletal muscle troponin activator which is being developed as a potential treatment for people living with SMA, COPD and certain other debilitating diseases and conditions associated with muscular weakness and/or fatigue. Astellas is conducting this Phase 2 clinical trial in collaboration with Cytokinetics.
CYTK: 10.09 (-0.24)
Cytokinetics Has Returned 19.1% Since SmarTrend Recommendation (CYTK)
Comtex SmarTrend(R) - Mon Jun 27, 1:48PM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 3 months, Cytokinetics has returned 19.14% as of today's recent price of $8.97.
CYTK: 10.09 (-0.24)
Cytokinetics Shares Up 19.9% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Fri Jun 17, 1:24AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on April 4th, 2016 at $7.53. In approximately 2 months, Cytokinetics has returned 19.87% as of today's recent price of $9.02.
CYTK: 10.09 (-0.24)
Cytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 3:05AM CDT
Cytokinetics, Incorporated (CYTK) saw its shares rise almost 7% in the last trading session.
CYTK: 10.09 (-0.24), ANIP: 55.38 (-1.13)
Cytokinetics to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue Jun 14, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the JMP Securities 2016 Life Sciences Conference on June 21, 2016 at 1:00 PM EDT at the St. Regis Hotel, New York, NY. Members of Cytokinetics' senior management team will also participate in the 3 Annual ROTH Healthcare Day on June 22, 2016 at The Dorchester Hotel in London, UK.
CYTK: 10.09 (-0.24)
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress
GlobeNewswire - Mon May 23, 6:30AM CDT
Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP
CYTK: 10.09 (-0.24), AMGN: 160.18 (-0.92)
Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
GlobeNewswire - Fri May 20, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.
CYTK: 10.09 (-0.24), SRPT: 21.37 (-1.25)
Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016
GlobeNewswire - Fri May 13, 3:00PM CDT
Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology, to be held May 21 - May 24, 2016 at the Fortezza da Basso in Florence, Italy.
CYTK: 10.09 (-0.24)
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire - Wed May 11, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 18, 2016 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.
CYTK: 10.09 (-0.24)
Cytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month
GlobeNewswire - Mon May 02, 6:34AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it will ring the Closing Bell at Nasdaq this afternoon in recognition of ALS Awareness Month and the company's commitment to education, awareness, research and development activities focused to amyotrophic lateral sclerosis (ALS). Cytokinetics' senior leadership team will be joined in this symbolic act by the leadership of the National, Golden West and New York Chapters of The ALS Association as well as people living with ALS and their loved ones.
CYTK: 10.09 (-0.24)
The ALS Association and Cytokinetics Ring in May as ALS Awareness Month at NASDAQ
PR Newswire - Sun May 01, 4:03PM CDT
May is ALS Awareness Month, an annual grassroots effort led by the ALS community and The ALS Association to raise awareness about amyotrophic lateral sclerosis (ALS) and move people to action in advancing the search for effective treatments and a cure. On Monday, May 2, The ALS Association is pleased to join Cytokinetics, Inc. (Nasdaq: CYTK), along with people living with ALS and their families, for the ringing of the closing bell at NASDAQ in New York City to kick off this year's campaign.
CYTK: 10.09 (-0.24)
Cytokinetics, Inc. (Nasdaq: CYTK) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Apr 29, 9:00AM CDT
What:
CYTK: 10.09 (-0.24), NDAQ: 66.43 (+0.55)
Cytokinetics, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the first quarter of 2016 were $8.4 million, compared to $4.4 million, during the same period in 2015. The net loss for the first quarter was $12.5 million, or $0.31 per basic and diluted share. This is compared to the net loss for the same period in 2015 of $8.9 million, or $0.23 per basic and diluted share. As of March 31, 2016, cash, cash equivalents and investments totaled $108.6 million.
CYTK: 10.09 (-0.24)
Cytokinetics to Announce First Quarter Results on April 28, 2016
GlobeNewswire - Thu Apr 14, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 28, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
CYTK: 10.09 (-0.24)
Cytokinetics to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:20 AM ET at the Westin Grand Central Hotel in New York, NY.
CYTK: 10.09 (-0.24)
Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical trial to evaluate the safety, pharmacokinetics and efficacy of omecamtiv mecarbil in Japanese subjects with heart failure and reduced ejection fraction. Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.
CYTK: 10.09 (-0.24), AMGN: 160.18 (-0.92)
Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALS
GlobeNewswire - Thu Mar 31, 6:30AM CDT
Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced a research collaboration to refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from Cytokinetics' clinical trials of tirasemtiv. Funded by Origent's receipt of a grant from The ALS Association, this joint research program will enable the first prospective validation of the predictive model in a clinical trial setting. Previously, the Origent models predicting both function and survival of ALS patients have been validated using internal and retrospective external datasets.
CYTK: 10.09 (-0.24)
Cytokinetics Has Returned 36.7% Since SmarTrend Recommendation (CYTK)
Comtex SmarTrend(R) - Tue Mar 29, 1:09PM CDT
SmarTrend identified a Downtrend for Cytokinetics (NASDAQ:CYTK) on December 29th, 2015 at $10.44. In approximately 3 months, Cytokinetics has returned 36.66% as of today's recent price of $6.61.
CYTK: 10.09 (-0.24)
37.3% Return Seen to Date on SmarTrend Cytokinetics Call (CYTK)
Comtex SmarTrend(R) - Tue Mar 22, 12:58AM CDT
SmarTrend identified a Downtrend for Cytokinetics (NASDAQ:CYTK) on December 29th, 2015 at $10.44. In approximately 3 months, Cytokinetics has returned 37.33% as of today's recent price of $6.54.
CYTK: 10.09 (-0.24)
